Jayson S. Brower
YOU?
Author Swipe
View article: Two-Year Outcomes of Prostatic Artery Embolization for Symptomatic Benign Prostatic Hyperplasia: An International, Multicenter, Prospective Study
Two-Year Outcomes of Prostatic Artery Embolization for Symptomatic Benign Prostatic Hyperplasia: An International, Multicenter, Prospective Study Open
View article: 102P Interim safety analysis of a phase II trial of cisplatin-sensitized radiation therapy and pembrolizumab for unresectable vulvar cancer
102P Interim safety analysis of a phase II trial of cisplatin-sensitized radiation therapy and pembrolizumab for unresectable vulvar cancer Open
Vulvar cancer is a rare disease with increasing incidence. Treatment can involve surgery and chemoradiation for local and regional disease, while systemic chemotherapy and immunotherapy are reserved for patients with distant metastases. Pa…
View article: Overall survival and toxicity of hepatocellular carcinoma Barcelona Clinic Liver Cancer B patients receiving Y90 radioembolization: analysis of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry
Overall survival and toxicity of hepatocellular carcinoma Barcelona Clinic Liver Cancer B patients receiving Y90 radioembolization: analysis of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry Open
The Bolondi subgroup classification stratifies OS, PFS and development of toxicity in patients treated with resin Y-90 microspheres. OS in subgroup 1 approaches 2.5 years and Grade 3 or greater hepatic toxicity profile in subgroups 1-3 is …
View article: Overall survival and toxicity of Y90 radioembolization for hepatocellular carcinoma patients in Barcelona Clinic Liver Cancer stage C (BCLC-C)
Overall survival and toxicity of Y90 radioembolization for hepatocellular carcinoma patients in Barcelona Clinic Liver Cancer stage C (BCLC-C) Open
Introduction National Comprehensive Cancer Network HCC guidelines recommend Y90 to treat BCLC-C patients only in select cases given the development of systemic regimens. We sought to identify ideal candidates for Y90 by assessing survival …
View article: Survival and Toxicities after <sup>90</sup>Y Transarterial Radioembolization of Metastatic Colorectal Cancer in the RESIN Registry
Survival and Toxicities after <sup>90</sup>Y Transarterial Radioembolization of Metastatic Colorectal Cancer in the RESIN Registry Open
Background Patients with unresectable, chemorefractory hepatic metastases from colorectal cancer have considerable mortality. The role of transarterial radioembolization (TARE) with yttrium 90 (90Y) microspheres is not defined because most…
View article: Abstract No. 115 Demographics and outcomes following Y90 radioembolization of hepatocellular carcinoma at transplant versus non-transplant centers: analysis of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry
Abstract No. 115 Demographics and outcomes following Y90 radioembolization of hepatocellular carcinoma at transplant versus non-transplant centers: analysis of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry Open
View article: Incidence and risk factors for sustained hepatic function toxicity 6 months after radioembolization: analysis of the radiation-emitting sir-spheres in non-resectable liver tumor (RESIN) registry
Incidence and risk factors for sustained hepatic function toxicity 6 months after radioembolization: analysis of the radiation-emitting sir-spheres in non-resectable liver tumor (RESIN) registry Open
Baseline liver function abnormalities prior to radioembolization is the strongest predictor of post-treatment Grade 3 toxicity with rates as high as 13.8%. Toxicity rates for specific lab values are affected by large volume treatments espe…
View article: Final Two-Year Outcomes for the Sentry Bioconvertible Inferior Vena Cava Filter in Patients Requiring Temporary Protection from Pulmonary Embolism
Final Two-Year Outcomes for the Sentry Bioconvertible Inferior Vena Cava Filter in Patients Requiring Temporary Protection from Pulmonary Embolism Open
The Sentry IVC filter provided safe and effective protection against PE, with a high rate of intended bioconversion and a low rate of device-related complications, through 2 years of follow-up.
View article: Abstract No. 602 Rationale and experimental design of the KNOCOUT PE trial: an international EKoSoNic® registry of the treatment and clinical outcomes of patients with pulmonary embolism
Abstract No. 602 Rationale and experimental design of the KNOCOUT PE trial: an international EKoSoNic® registry of the treatment and clinical outcomes of patients with pulmonary embolism Open
View article: One-Year Analysis of the Prospective Multicenter SENTRY Clinical Trial: Safety and Effectiveness of the Novate Sentry Bioconvertible Inferior Vena Cava Filter
One-Year Analysis of the Prospective Multicenter SENTRY Clinical Trial: Safety and Effectiveness of the Novate Sentry Bioconvertible Inferior Vena Cava Filter Open
View article: A Randomized Trial of the Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Intermediate-Risk Pulmonary Embolism
A Randomized Trial of the Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Intermediate-Risk Pulmonary Embolism Open
View article: 3:18 PM Abstract No. 263 Multicenter evaluation of yttrium-90 selective internal radiation therapy for the treatment of metastatic pancreatic adenocarcinoma
3:18 PM Abstract No. 263 Multicenter evaluation of yttrium-90 selective internal radiation therapy for the treatment of metastatic pancreatic adenocarcinoma Open
View article: Prospective, multicenter evaluation of targeted radiofrequency ablation (t-RFA) and vertebral augmentation (VA) prior to or following radiation therapy (RT) to treat painful metastatic vertebral body tumors (STARRT Study): Interim analysis
Prospective, multicenter evaluation of targeted radiofrequency ablation (t-RFA) and vertebral augmentation (VA) prior to or following radiation therapy (RT) to treat painful metastatic vertebral body tumors (STARRT Study): Interim analysis Open
View article: Multicenter prospective clinical series evaluating targeted-radiofrequency ablation (t-RFA) in the treatment of painful spine metastases
Multicenter prospective clinical series evaluating targeted-radiofrequency ablation (t-RFA) in the treatment of painful spine metastases Open